Meeting Banner
Abstract #3597

In Vivo 1H MRS Assessment of Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Antipsychotic-Nave First-Episode Schizophrenia

Camilo de la Fuente-Sandoval1, Pablo L. Ortiz2, Xiangling Mao3, Patricia Alavarado-Alanis4, Oscar Rodrguez-Mayoral5, Francisco Reyes-Madrigal4, Ariel Graff-Guerrero6, Rodolfo Solis-Vivanco7, Rafael Favila8, Dikoma C. Shungu3

1Neuropsychiatry & Laboratory of Experimental Psychiatry, Instituto Nacional de Neurologa y Neurociruga (INNN), Mexico City, Distrito Federal, Mexico; 2Education, INNN, Mexico City, Distrito Federal, Mexico; 3Radiology, Weill Cornell Medical College, New York, NY, United States; 4Laboratory of Experimental Psychiatry, INNN, Mexico City, Distrito Federal, Mexico; 5Early Psychosis Intervention, Hospital Fray Bernardino Alvarez, Mexico City, Distrito Federal, Mexico; 6Multimodal Neuroimaging Schizophrenia Group, Centre for Addiction and Mental Health, Toronto, ON, Canada; 7Laboratory of Neuropsychology, INNN, Mexico City, Distrito Federal, Mexico; 8MR Advanced Applications, GE Healthcare, Mexico City, Distrito Federal, Mexico

This study used 1H MRS to measure and compare brain GABA and glutamatergic compound (Glx) levels in antipsychotic-nave schizophrenia patients during first-episode psychosis (FEP) and age- and sex-matched healthy control (HC) subjects, and found regional elevations or strong trend-level elevations of both neurotransmitters in the FEP subjects.